Clinical Evaluation of Recombinant Factor VIII Preparation (Kogenate) in Previously Treated Patients with Hemophilia A: Descriptive Meta-Analysis of Post-Marketing Study Data-Reference-Cited by-同舟云学术

Clinical Evaluation of Recombinant Factor VIII Preparation (Kogenate) in Previously Treated Patients with Hemophilia A: Descriptive Meta-Analysis of Post-Marketing Study Data

Published:2006-08-01 Issue:2 Volume:84 Page:158-165
ISSN:0925-5710
Container-title:International Journal of Hematology
language:
Short-container-title:International Journal of Hematology

Author:

Yoshioka A.,Fukutake K.,Takamatsu J.,Shirahata A.

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://www.springerlink.com/index/pdf/10.1532/IJH97.06019

Reference27 articles.

1. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature. 1984;312:326-330.

2. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature. 1984;312:330-337.

3. Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A: Recombinant Factor VIII Study Group. N Engl J Med. 1990;323:1800-1805.

4. Yoshioka A. Advances in hemophilia and other coagulation disorders: recombinant factor VIII preparations. Int J Pediatr Hematol Oncol. 1994;1:491-497.

5. Fukui H, Yoshioka A, Shima M, et al. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A. Int J Hematol. 1991;54:419-427.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitors in hemophilia: association with surgery plans and outcomes in a retrospective cohort study;Research and Practice in Thrombosis and Haemostasis;2023-10

2. Recombinant blood products and therapeutic enzymes: An update;The Future of Pharmaceutical Product Development and Research;2020

3. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study;Journal of Korean Medical Science;2018

4. Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study;Current Medical Research and Opinion;2017-04-25

5. Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series;Haemophilia;2017-02-15